✦ LIBER ✦

Cyclophosphamide and liposomal-encapsulated doxorubicin (MYOCET®) in elderly women with HER-2 negative locally advanced or metastatic breast cancer: Preliminary results of a multicenter phase II trial from the Hellenic Oncology Research Group

✍ Scribed by Karampeazis⁎, A.; Ardavanis, A.; Kentepozidis, N.; Nikolaou, Ch.; Bozionelou, V.; Papakotoulas, P.; Tryfonidis, K.; Saloustros, E.; Mavroudis, D.; Georgoulias, V.; Vamvakas, L.

Book ID: 122892393
Publisher: Elsevier
Year: 2012
Tongue: English
Weight: 80 KB
Volume: 3
Category: Article
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2012.10.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel and bevacizumab as first-line

Paclitaxel and bevacizumab as first-line treatment in elderly women with HER-2 negative locally advanced or metastatic breast cancer: Preliminary results a multicenter phase II trial from Hellenic Oncology Research Group

✍ Vamvakas, L.; Karampeazis⁎, A.; Nikolaou, Ch.; Ardavanis, A.; Saloustros, E.; Ka 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 71 KB

Results of a phase II study of liposomal

Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

✍ J Baselga; M.A Climent; A Lluch; J Hornedo; P Gascon; A.T Sanchez; V Guillem; H 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 173 KB

P.39 Docetaxel plus epirubicin (DE) vs d

P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Varda 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB